Neurocrine Biosciences Inc. (NASDAQ:NBIX) was up 3.7% on Monday . The company traded as high as $50.43 and last traded at $50.38, with a volume of 377,073 shares. The stock had previously closed at $48.57.

A number of equities research analysts recently weighed in on NBIX shares. Jefferies Group reissued a “buy” rating on shares of Neurocrine Biosciences in a research note on Wednesday, June 8th. Piper Jaffray Cos. reissued an “overweight” rating and set a $96.00 price target on shares of Neurocrine Biosciences in a research note on Tuesday, June 7th. HC Wainwright reissued a “buy” rating on shares of Neurocrine Biosciences in a research note on Friday, August 5th. Cowen and Company reissued a “buy” rating and set a $65.00 price target on shares of Neurocrine Biosciences in a research note on Friday, August 5th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $63.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, June 1st. One investment analyst has rated the stock with a sell rating and ten have issued a buy rating to the company. Neurocrine Biosciences has a consensus rating of “Buy” and an average price target of $63.90.

The company’s market capitalization is $4.43 billion. The stock has a 50 day moving average of $48.54 and a 200 day moving average of $43.76.

In other news, Director Richard F. Pops sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 25th. The shares were sold at an average price of $46.72, for a total value of $700,800.00. Following the sale, the director now directly owns 15,464 shares in the company, valued at approximately $722,478.08. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Christopher Flint Obrien sold 12,500 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $48.73, for a total transaction of $609,125.00. Following the completion of the sale, the insider now owns 55,044 shares in the company, valued at $2,682,294.12. The disclosure for this sale can be found here.

Other large investors have bought and sold shares of the company. Westfield Capital Management Co. LP increased its stake in Neurocrine Biosciences by 6.6% in the fourth quarter. Westfield Capital Management Co. LP now owns 1,221,642 shares of the company’s stock valued at $69,108,000 after buying an additional 75,797 shares in the last quarter. BlackRock Advisors LLC increased its stake in Neurocrine Biosciences by 28.3% in the fourth quarter. BlackRock Advisors LLC now owns 1,069,299 shares of the company’s stock valued at $60,490,000 after buying an additional 235,700 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in Neurocrine Biosciences by 5.2% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 332,166 shares of the company’s stock valued at $18,791,000 after buying an additional 16,312 shares in the last quarter. Finally, I.G. Investment Management LTD. acquired a new stake in Neurocrine Biosciences during the fourth quarter valued at approximately $2,546,000.

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.